Anavex Life Sciences Corp.
NASDAQ:AVXLBiotechnology
-$0.04 today
- Market cap
- $66.69M
- Beta
- 1.12
- P/E (TTM)
- -5.9
- EPS (TTM)
- -$0.45
Volume 1.06M
Average 1.39M
AVXL Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Anavex Life Sciences Corp.NASDAQ: AVXL
Weighted Avg Shares · Q1 FY2026 · quarter ended Dec 2025
Weighted avg shares growth accelerates
Q1 FY2026 weighted avg shares of 89.03M shares rose 5.0% year over year, ahead of the +2.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 3.7% from the prior quarter. Over 3 fiscal years it compounded at +3.5% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +5.0% holds above the trailing-twelve-month pace of +2.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 85.29M USD
- Year-over-year change
- +2.2%
- 4-year CAGR
- +5.1%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 85.29M | +2.2% |
| FY2024 | 2024-09-30 | 83.47M | +4.6% |
| FY2023 | 2023-09-30 | 79.79M | +3.7% |
| FY2022 | 2022-09-30 | 76.91M | +10.2% |
| FY2021 | 2021-09-30 | 69.8M | — |
Weighted Avg Shares vs competitors
How AVXL compares with its peers on the latest reported figures
- AVXL's LTM Dec 2025 weighted avg shares of 86.34M shares is the 4th highest of the 10 companies compared; the peer median is 80.99M shares.
- Its year-over-year change of +2.9% is the 8th highest of 10, against a peer median of +13.7%.
- Over three fiscal years its annual growth of +3.5% compares with a peer median of +14.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | 310.86M | +9.7% | +32.5% | |
| LTM Mar 2026 | 160.38M | +90.3% | +28.0% | |
| LTM Mar 2026 | 143.73M | +23.4% | +14.6% | |
| LTM Dec 2025 | 86.34M | +2.9% | +3.5% | |
| LTM Mar 2026 | 83.89M | +18.5% | +13.4% | |
| LTM Mar 2026 | 80.99M | +13.7% | +21.2% | |
| LTM Mar 2026 | 68.65M | -4.9% | +6.9% | |
| LTM Mar 2026 | 65.6M | +4.1% | +30.0% | |
| LTM Mar 2026 | 51.84M | +1.8% | +6.1% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | 44.83M | +33.4% | +4.6% |
| Peer median (excluding AVXL) | 80.99M | +13.7% | +14.6% | |
Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.98M | 37.92M | 43.72M | 41.84M | 37.59M |
| Selling, General & Admin | 9.02M | 13.07M | 12.05M | 11.04M | 13.82M |
| Operating Expenses | 42M | 50.99M | 55.76M | 52.88M | 51.41M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (37.64M) | (47.62M) | (46.54M) | (43M) | (46.38M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (42M) | (50.99M) | (55.76M) | (52.88M) | (51.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 26K | 947K | 6.52M | 7.32M | 4.68M |
| Interest Expense | 0 | 0 | 964K | 0 | 0 |
| Other Income / Expenses | 4.36M | 3.37M | 8.26M | 9.88M | 5.03M |
| Income Before Tax | (37.64M) | (47.62M) | (47.51M) | (43M) | (46.38M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 268K | 358K | 0 | 0 | 0 |
| Net Income | (37.91M) | (47.98M) | (47.51M) | (43M) | (46.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.54) | (0.62) | (0.60) | (0.52) | (0.54) |
| EPS (Diluted) | (0.54) | (0.62) | (0.60) | (0.52) | (0.54) |
| Weighted Avg Shares | 69.8M | 76.91M | 79.79M | 83.47M | 85.29M |
| Weighted Avg Shares (Diluted) | 69.8M | 76.91M | 79.79M | 83.47M | 85.29M |
Anavex Life Sciences Corp.
NASDAQ:AVXL
Intrinsic Alpha fair value
Locked
Current Price
$0.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.